Page 57 - ITPS-7-2

INNOSC Theranostics and
Pharmacological Sciences Cardiac metabolism in health and disease

2023;389(2):107-117. doi: 10.1161/CIRCRESAHA.112.268128
doi: 10.1056/NEJMoa2215025 26. Gosteli-Peter MA, Schmid C, Zapf J. Triiodothyronine
increases glucose transporter isotype 4 mRNA expression,
15. Christakis GT, Weisel RD, Mickle DA, et al. Right
ventricular function and metabolism. Circulation. glucose transport, and glycogen synthesis in adult rat
1990;82(5 Suppl):IV332-IV340. cardiomyocytes in long-term culture. Biochem Biophys Res
Commun. 1996;221(3):521-524.
16. Sato K, Kashiwaya Y, Keon CA, et al. Insulin, ketone
bodies, and mitochondrial energy transduction. FASEB J. doi: 10.1006/bbrc.1996.0629
1995;9(8):651-658. 27. Becker C, Sevilla L, Tomas E, Palacin M, Zorzano A,
Fischer Y. The endosomal compartment is an insulin-
doi: 10.1096/fasebj.9.8.7768357
sensitive recruitment site for GLUT4 and GLUT1
17. Mudaliar S, Alloju S, Henry RR. Can a shift in fuel energetics glucose transporters in cardiac myocytes. Endocrinology.
explain the beneficial cardiorenal outcomes in the EMPA- 2001;142(12):5267-5276.
REG OUTCOME study? A unifying hypothesis. Diabetes
Care. 2016;39(7):1115-1122. doi: 10.1210/endo.142.12.8555
28. Fischer Y, Thomas J, Sevilla L, et al. Insulin-induced
doi: 10.2337/dc16-0542
recruitment of glucose transporter 4 (GLUT4) and GLUT1
18. Ferrannini E, Mark M, Mayoux E. CV protection in in isolated rat cardiac myocytes. Evidence of the existence
the EMPA-REG OUTCOME Trial: A “thrifty substrate” of different intracellular GLUT4 vesicle populations. J Biol
hypothesis. Diabetes Care. 2016;39(7):1108-1114. Chem. 1997;272(11):7085-7092.
doi: 10.2337/dc16-0330 doi: 10.1074/jbc.272.11.7085
19. Shao D, Tian R. Glucose transporters in cardiac metabolism 29. Mueckler M, Thorens B. The SLC2 (GLUT) family
and hypertrophy. Compr Physiol. 2015;6(1):331-351. of membrane transporters. Mol Aspects Med.
doi: 10.1002/cphy.c150016 2013;34(2-3):121-138.
doi: 10.1016/j.mam.2012.07.001
20. Lopaschuk GD, Ussher JR, Folmes CD, Jaswal JS,
Stanley WC. Myocardial fatty acid metabolism in health and 30. Zhou L, Cryan EV, D’Andrea MR, Belkowski S, Conway BR,
disease. Physiol Rev. 2010;90(1):207-258. Demarest S. Human cardiomyocytes express high level
doi: 10.1152/physrev.00015.2009 of Na+/glucose cotransporter 1 (SGLT1). J Cell Biochem.
2003;90(2):339-346.
21. Szablewski L. Glucose transporters in healthy heart and in
cardiac disease. Int J Cardiol. 2017;230:70-75. doi: 10.1002/jcb.10631
doi: 10.1016/j.ijcard.2016.12.083 31. Banerjee SK, McGaffin KR, Pastor-Soler NM, Ahmad F.
SGLT1 is a novel cardiac glucose transporter that is perturbed
22. Schwenk RW, Luiken JJ, Bonen A, Glatz JF. Regulation of in disease states. Cardiovasc Res. 2009;84(1):111-118.
sarcolemmal glucose and fatty acid transporters in cardiac
disease. Cardiovasc Res. 2008;79(2):249-258. doi: 10.1093/cvr/cvp190.
32. Laffel L. Ketone bodies: A review of physiology,
doi: 10.1093/cvr/cvn116
pathophysiology and application of monitoring to diabetes.
23. Ussher JR, Folmes CD, Keung W, et al. Inhibition of serine Diabetes Metab Res Rev. 1999;15(6):412-426.
palmitoyl transferase I reduces cardiac ceramide levels and
increases glycolysis rates following diet-induced insulin doi: 10.1002/(sici)1520-7560(199911/12)15:6<412::aid-
resistance. PLoS One. 2012;7(5):e37703. dmrr72>3.0.co;2-8
doi: 10.1371/journal.pone.0037703 33. Akram M. A focused review of the role of ketone bodies in
health and disease. J Med Food. 2013;16(11):965-967.
24. Dyck JR, Cheng JF, Stanley WC, et al. Malonyl coenzyme
a decarboxylase inhibition protects the ischemic heart by doi: 10.1089/jmf.2012.2592
inhibiting fatty acid oxidation and stimulating glucose 34. Cahill GF Jr. Fuel metabolism in starvation. Annu Rev Nutr.
oxidation. Circ Res. 2004;94(9):e78-e84. 2006;26:1-22.
doi: 10.1161/01.RES.0000129255.19569.8f doi: 10.1146/annurev.nutr.26.061505.111258
25. Kolwicz SC Jr., Olson DP, Marney LC, Garcia-Menendez L, 35. Veech RL. The therapeutic implications of ketone bodies:
Synovec RE, Tian R. Cardiac-specific deletion of acetyl the effects of ketone bodies in pathological conditions:
CoA carboxylase 2 prevents metabolic remodeling Ketosis, ketogenic diet, redox states, insulin resistance, and
during pressure-overload hypertrophy. Circ Res. mitochondrial metabolism. Prostaglandins Leukot Essent
2012;111(6):728-738. Fatty Acids. 2004;70(3):309-319.

Volume 7 Issue 2 (2024) 8 doi: 10.36922/itps.2302